tradingkey.logotradingkey.logo
Discount
Tradingkey

Bristol-Myers Squibb Co

BMY
Add to Watchlist
59.170USD
+0.830+1.42%
Market hours 11/20, 14:41(ET)
120.95BMarket Cap
16.56P/E TTM

Today

+1.42%

5 Days

-5.05%

1 Month

+0.58%

6 Months

+3.68%

Year to Date

+14.58%

1 Year

+34.97%

Key Figures

58.990Open
59.795High
2.21MVolume
16.56P/E TTM
8.79P/E Dynamic
2.500Dividend TTM
0.11%Turnover Ratio
58.340Prev. Close
57.878Low
130.78MTurnover
LossP/E Static
5.17P/B
4.22%Div Yield TTM
8.13%ROA
67.93652wk High
0.23Volume Ratio
-8.95BNet Profit
2.04BShares
3.5723EPS TTM
0.24Beta
38.84%ROE
43.58152wk Low
3.29%Amplitude
64.87%Gross Margin
120.95BMarket Cap
4.36Reward/Risk
1.75%Risk Rate
Recent
Analysis
Transcripts
Bristol-Myers Squibb Co Stock (BMY) Moved Down by 3.26% on Nov 17: What Signal Does It Send?

• Bristol Myers Squibb shares fell due to institutional profit-taking and revenue transition concerns. • Investors worry about the loss of exclusivity impacting top-tier legacy revenue drivers. • The company reports $48.19 billion in annual revenue and $7.05 billion net profit.

TradingKeyTue, Nov 17
Bristol-Myers Squibb Co Stock (BMY) Moved Up by 3.39% on Oct 20: Key Drivers Unveiled

• Bristol Myers Squibb stock gained momentum ahead of major medical conference presentations. • Analysts upgraded targets following strong clinical pipeline updates and commercial growth assets. • The company reported $48.19B annual revenue and $7.05B net profit.

TradingKeyTue, Oct 20
Moderna Inc Stock (MRNA) Moved Down by 5.73% on Oct 12: Facts Behind the Movement

• Moderna shares declined as investors engaged in profit-taking following recent gains. • Wall Street analysts highlighted valuation friction due to unprofitability and high cash burn. • The company reported an annual revenue of $1.94B and a net loss.

TradingKeyMon, Oct 12
Bristol-Myers Squibb Co Stock (BMY) Moved Down by 3.35% on Oct 12: What Signal Does It Send?

• Bristol-Myers Squibb stock fell despite positive Phase 3 clinical trial results. • RYZ101 met its endpoint, while admilparant showed mixed efficacy at different doses. • Technical indicators show a sell signal with an RSI of 29.182.

TradingKeyMon, Oct 12
Bristol-Myers Squibb Co Stock (BMY) Moved Down by 3.56% on Oct 5: What Investors Need To Know

• Leerink Partners downgraded Bristol-Myers Squibb and cut its price target. • Approaching patent cliffs for Eliquis and Opdivo threaten future revenues. • U.S. Medicare price negotiations create broader sector policy headwinds.

TradingKeyMon, Oct 5
Immunitybio Inc Stock (IBRX) Moved Up by 11.15% on Sep 30: What Signal Does It Send?

• ImmunityBio rallied due to strong commercial momentum for its immunotherapy ANKTIVA. • Wall Street analysts maintain a bullish consensus with an average price target of $12.75. • The company reported $113.29M in annual revenue and a net loss of $351.40M.

TradingKeyWed, Sep 30

Bristol-Myers Squibb Co's Score

0.06vs previous score
Forecast7.00
Financial Health8.99
Technical2.92
Valuation Dimensions9.12
Institutional Confidence7.00
Risk Assessment9.36

Media Coverage

Coverage Level

Very Low
Very High
Positive

Analyst Rating

Strong Buy
Buy
Hold
Sell
Strong Sell
BuyCurrent Rating
64.962Target Price
+3.97%Upside Space
Current Rating2026-112026-102026-092026-082026-072026-062026-052026-04
Strong Buy56555555
Buy66666777
Hold1817181819181818
Sell11222222
Strong Sell00000000

Bristol-Myers Squibb Co Technical Analysis

1m
5m
15m
30m
1h
2h
4h
D
W
M
1m
5m
15m
D
Technical Indicators
Sell
Summary
Sell
Moving Average
Strong sell

Bristol-Myers Squibb Co Latest Earnings Call Transcripts

Bristol Myers Squibb (BMY) Q3 2026 Earnings Call: Revenue Growth and Higher EPS Guidance

Bristol Myers Squibb Q3 2026 earnings call: revenue rose 7% to $13.1 billion, growth portfolio sales increased 12%, and EPS guidance was raised.

Financial Indicators

Currency: USD
Quarterly
Quarterly
Annual
Relevant data have not been disclosed by the company yet.
Currency: USD
Quarterly
Quarterly
Annual
Relevant data have not been disclosed by the company yet.

Earnings

Next reporting date
--
Reporting Period
2026Q3
Earnings / Forecast
1.06/1.28
Revenue / Forecast
13.07B/12.71B

Bristol-Myers Squibb Co Profile

SectorPharmaceuticals
Ticker SymbolBMY
Number of employees34100
CountryUnited States of America

Ownership

ShareholdersProportion
Vanguard Capital Management, LLC6.48%
BlackRock Institutional Trust Company, N.A.5.11%
State Street Investment Management (US)4.80%
Charles Schwab Investment Management, Inc.3.49%
Shareholder TypesProportion
Investment Advisor44.07%
Investment Advisor/Hedge Fund27.75%
Research Firm3.12%
Pension Fund2.89%

FAQs

What is the current price of Bristol-Myers Squibb Co (BMY)?

The current price of Bristol-Myers Squibb Co (BMY) is 58.34.

What is the symbol of Bristol-Myers Squibb Co?

The ticker symbol of Bristol-Myers Squibb Co is BMY.

What is the 52-week high of Bristol-Myers Squibb Co?

The 52-week high of Bristol-Myers Squibb Co is 67.94.

What is the 52-week low of Bristol-Myers Squibb Co?

The 52-week low of Bristol-Myers Squibb Co is 43.58.

What is the market capitalization of Bristol-Myers Squibb Co?

The market capitalization of Bristol-Myers Squibb Co is 119.25B.

Is Bristol-Myers Squibb Co (BMY) currently rated as Buy, Hold, or Sell?

According to analysts, Bristol-Myers Squibb Co (BMY) has an overall rating of Buy, with a price target of 64.96.

What is the Earnings Per Share (EPS TTM) of Bristol-Myers Squibb Co (BMY)?

The Earnings Per Share (EPS TTM) of Bristol-Myers Squibb Co (BMY) is 3.57.
tradingkey.logotradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.